Skip to search formSkip to main contentSkip to account menu

Rotigotine

Known as: (6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol, (+--)-5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol, rotigotine, (+--)- 
National Institutes of Health

Related topics

Related topics

12 relations
24 HR Rotigotine 0.0417 MG/HR Transdermal System24 HR Rotigotine 0.0417 MG/HR Transdermal System [Neupro]24 HR Rotigotine 0.25 MG/HR Transdermal System24 HR Rotigotine 0.333 MG/HR Transdermal System

Broader (3)

Dopamine AgonistsTetrahydronaphthalenesThiophenes

Narrower (2)

N 0437Rotigotine CDS

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Vascular Parkinsonism: Motor and Non-Motor Response on Treatmentwith Rotigotine
To date dopaminergic therapy has shown unsatisfactory effect on vascular Parkinsonism symptoms and related disturbances. In this… 
Review
2015
Review
2015
Schlaf und Schlafstörungen beim alten Menschen
ZusammenfassungDas Restless-legs-Syndrom (RLS) ist mit einer Prävalenz von etwa 10 % eine häufige Erkrankung. Frauen sind öfter… 
2015
2015
Transdermal delivery system, including rotigotine
自己接着性層構造中に治療有効量のロチゴチン塩基を含む、ロチゴチンの経皮投与のための経皮治療システムであって、該自己接着性層構造が、Ａ）裏打ち層、ならびにＢ）ロチゴチン含有二相層であって、該二相層が、ａ）７５％〜１００％のポリマーまたはポリマー混合物を含む組成物を有する外部相と、ｂ）ロチゴチン塩基を含む組成物を有する内部相とを有し、該内部相が該外部相中に分散したデポジットを形成し、該内部相がｉ． ロチゴチン塩基と、ｉｉ． ポリマー群：− 少なくとも８０、または８０〜２００のＫ値を有するポリビニルピロリドン、− ８０未満、または１０〜７９のＫ値を有するポリビニルピロリドン、− ビニルカプロラクタム、酢酸ビニルおよびエチレングリコールのコポリマー、− ビニルピロリドンおよび酢酸ビニルのコポリマー、− エチレンおよび酢酸ビニルのコポリマー、− ポリエチレングリコール、− ポリプロピレングリコール、− アクリルポリマー、− 変性セルロースのうちの少なくとも２つから選択される少なくとも２つの親水性ポリマーを含むポリマー混合物とを含み、内部相中のポリマー混合物が、前記ロチゴチン塩基が内部相中のポリマー混合物と固溶体を形成するために十分な量で存在する、前記ロチゴチン含有二相層、ならびにＣ）場合により、追加の皮膚接触層を含む、前記経皮治療システム。 
2015
2015
Transdermal delivery system containing rotigotine
Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of… 
2009
2009
Amorphous rotigotine (Rotigotine) transdermal system
The present invention relates to a transdermal delivery device comprising a backing layer, the adhesive matrix layer and a… 
2003
2003
Improved transdermal delivery system for the administration of rotigotine
An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive… 
2003
2003
Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
1. Use of a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol / l, wherein the… 
2003
2003
System for transdermal administering of rotigotine base
The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6… 
2002
2002
Transdermal therapeutic system for parkinson`s disease inducing high plasma levels of rotigotine
This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm and containing 0… 
2002
2002
Hot melt TTS for administering rotigotine and method for its production and use of rotigotine in the production of a TTS in a hot melt procedure
Transdermal therapeutic system (TTS) containing an active substance-containing adhesive matrix, characterized in that the…